Clinical Trial Search

Primary: Number of Patients Who Completed All Planned Therapy — 45 participants

Primary: Estimate Progression-free Survival — 16.9; 8.3 Months

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010

Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants

Primary: Number of Participants With Dose-Limiting Toxicities — 1 Participants

Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants

Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants

Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants

Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants

Primary: Clinical Response — 3; 30; 11; 3 participants

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…

Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors…

Primary: Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up — 12.9; 7.5 percentage of…

Primary: Phase Ib Primary Outcome: Proportion of Patients Who Experienced DLTs Attributable to Palbociclib, Tucatinib, or Both — 100; 65; 100 percentage of participants

Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants

Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants

Primary: Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H. — 0.978; 0.979 probability of…

Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months

Primary: 16-week Progression Free Survival — 58.2; 77.8 percentage of participants

Primary: Optimal Dose of RAD001 in Combination With Trastuzumab (Phase I) — 10 mg

Primary: Overall Response Rate (ORR) — 30 percentage of participants

Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants

Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF

Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…

Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months

Primary: Pathologic Complete Response (pCR) — 27 participants

Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants

Primary: Objective Response Rate (ORR) — 30.8; 31.0; 55.6 percentage of participants

Primary: Percentage of Patients Who Are Progression Free at 6 Months or Later. — 86 percentage of partcipants